Scientific corner

Efficacy of cytapheresis for induction therapy and extra-intestinal skin manifestations of ulcerative colitis

Tomoyoshi Shibuya,Osamu Nomura,Kei Nomura,Mayuko Haraikawa,Keiichi Haga,Dai Ishikawa,Taro Osada,Ken Yamaji,Shigaku Ikeda,Akihito Nagahara

Ther Apher Dial 2022 Mar 5. doi: 10.1111/1744-9987.13823. Online ahead of print.

Introduction: In recent years, the prevalence of inflammatory bowel diseases has been increasing in Japan due to the westernization of lifestyles. Many patients have been reported to have extra-intestinal manifestations (EIMs) at least once. Skin lesions occur with a high degree of frequency among EIMs, with erythema nodosum (EN) and pyoderma gangrenosum (PG) the main complications. Cytapheresis is again attracting attention as a treatment with few side effects. Methods: We investigated the therapeutic effect of cytapheresis on ulcerative colitis (UC) and cutaneous EIMs. Between 2008 and 2021, 240 patients with active UC had induction therapy by cytapheresis at our hospital. Results: Remission and response rates were 50.0% and 67.5%, respectively. Apheresis was performed on seven patients with PG and five patients with EN with a good response. Serious adverse events were not observed. Conclusion: This retrospective assessment of efficacy showed that EN and PG responded favorably to cytapheresis.

https://pubmed.ncbi.nlm.nih.gov/35247233/

Scientific corner

Adsorptive Granulocyte and Monocyte Apheresis Is Effective in Ulcerative Colitis Patients Both with and without Concomitant Prednisolone

Keiji Matsuda 1 2Kohei Ohno 1Yuka Okada 1Takahiro Yagi 1Mitsuo Tsukamoto 1Yoshihisa Fukushima 1Atsushi Horiuchi 1Ryu Shimada 1 2Tsuyoshi Ozawa 1 2Tamuro Hayama 1 2Takeshi Tsuchiya 1 2Junko Tamura 1Hisae Iinuma 1Keijiro Nozawa 1 2Hitoshi Aoyagi 2 3Akari Isono 2 3Koichiro Abe 2 3Shinya Kodashima 2 3Takatsugu Yamamoto 2 3Yoshitaka Kawasaki 4Yoshifuru Tamura 4Yuko Sasajima 5Fukuo Kondo 5Yojiro Hashiguchi 1 2 , Inflamm Intest Dis, 2020 Feb;5(1):36-41.

The effect of GMA with concomitant PSL (Prednisolone) and that of GMA without PSL were not different, and GMA was effective irrespective of PSL administration. The present study showed that GMA had efficacy and led many UC patients treated by PSL to be steroid free with no safety concern in the real world, although there is the possibility of recruitment bias due to the retrospective nature of the study.

https://pubmed.ncbi.nlm.nih.gov/32232053/

https://www.karger.com/Article/Pdf/505484

Scientific corner

Retrospective Single Center Study of Granulocyte Monocyte Adsorption Apheresis Treatment in Inflammatory Bowel Disease.

Kajsa Edfors 1Dagny Ståhlberg 1Charlotte Söderman 1 , Ther Apher Dial. 2016 Feb;20(1):79-85.

 Most frequently reported was headache (N = 4). GMA seems to be a valuable adjuvant treatment regime in the care of patients with refractory IBD.

https://pubmed.ncbi.nlm.nih.gov/26841133/

Scientific corner

Cytapheresis in patients with severe ulcerative colitis after failure of intravenous corticosteroid: a long-term retrospective cohort study

Ken Fukunaga 1Kazuko NagaseTakeshi KusakaNobuyuki HidaYoshio OhdaKoji YoshidaKatsuyuki TozawaKoji KamikozuruM IimuroShiro NakamuraHiroto MiwaTakayuki Matsumoto, Gut Liver. 2009 Mar;3(1):41-7. doi: 10.5009/gnl.2009.3.1.41

This study suggest that CAP is an effective therapy in patients who are refractory to conventional medications including iv corticosteroid. Increased remission rates should be expected in refractory patients with moderately severe UC.

https://pubmed.ncbi.nlm.nih.gov/20479900/

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2871568/pdf/gnl-3-41.pdf

Scientific corner

A retrospective search for predictors of clinical response to selective granulocyte and monocyte apheresis in patients with ulcerative colitis

Yasuo Suzuki 1Naoki YoshimuraKatsuyuki FukudaKoji ShiraiYasushi SaitoAbbi R Saniabadi

Dig Dis Sci.  2006 Nov;51(11):2031-8. doi: 10.1007/s10620-006-9199-9. Epub 2006 Sep 27.

Recently, selective granulocytapheresis (Adacolumn) has appeared as a new treatment for patients with inflammatory bowel disease. This study sought to determine predictors of response to this new nonpharmacologic mode of therapy by retrospectively evaluating 28 patients who received granulocytapheresis after experiencing active ulcerative colitis (UC). Between April 2000 and March 2004, 28 consecutive patients received granulocytapheresis for active UC with the Adacolumn, which is filled with cellulose acetate beads as the column leukocytapheresis carriers; the carriers adsorb granulocytes, monocytes/macrophages, and a small fraction of lymphocytes (FcgammaR and complement receptors bearing leukocytes). Each patient could receive up to 10 Adacolumn sessions, at 2 sessions per week. In 2004, clinical response was retrospectively evaluated. Seven days after the last Adacolumn session, 20 of 28 patients had remission (colitis activity index [CAI] < or =4) including all 8 patients who had their first UC episode. The mean duration of UC in the 8 first episode cases was 3.4 months compared with 40.2 months for all 28 patients and 65.4 months for the 8 nonresponders. The response to Adacolumn was independent of basal CAI. The 8 nonresponders were given conventional medication (CM) or cyclosporine (CsA) if the former failed. Two responded to CM, 3 to CsA, and 3 underwent colectomy. First UC episode and short disease duration appear good predictors of response to granulocytapheresis. Selective granulocytapheresis might be an effective first-line treatment.

https://pubmed.ncbi.nlm.nih.gov/17004123/

https://link.springer.com/article/10.1007%2Fs10620-006-9199-9

Contact UsFor more information

Contact Us